<DOC>
	<DOCNO>NCT01313117</DOCNO>
	<brief_summary>This study do peripheral neuropathy , condition interrupt sensation limb , common side effect paclitaxel . There evidence alpha lipoic acid ( ALA ) , antioxidant compound , protect neuron exposure paclitaxel . The purpose study assess safety tolerability ALA find best dose ALA patient receive chemotherapy .</brief_summary>
	<brief_title>Alpha-lipoic Acid Patients Risk Paclitaxel Induced Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Inclusion Criteria 1 . Diagnosis Breast cancer . 2 . Breast cancer must meet following criterion : Early stage breast cancer ( stage I , IIA ) must estrogen receptor ( ER ) positive AND low tumor grade ( histopathologic grade 1 2 ) Locally advanced breast cancer ( LABC ) ( stage IIB , IIIA , IIB define Union International Cancer Control American Joint Committee Cancer ) must ER positive , HER2 positive HER2 negative , AND satisfy follow requirement : high endocrine responsiveness ( define great 50 % tumor cell stain hormone receptor ) , Grade 1 2 histological grade , less 4 node positive , absence extensive peritumoral vascular invasion , AND pathological tumor size le 5 cm . Inflammatory breast cancer ( IBC ) ( stage IIIC ) Metastatic breast cancer ( stage IV ) 3 . Must receive single agent paclitaxel prescribe chemotherapy regimen . 4 . Age &gt; 18 year . There upper age limit participation study . 5 . Required lab value : AST , ALT , creatinine 6 . Women childbearing potential sexually active male must agree use contraception study . 7 . ECOG performance status 0,1,2 8 . All patient must give sign , informed consent . Exclusion Criteria 1 . Breast cancer meeting follow criterion : Breast cancer stage 0 Early stage breast cancer ( stage I , IIA ) ER negative OR high tumor grade ( histopathologic grade great 2 ) Stages I , II , IIIA triple negative breast cancer ( negative estrogen receptor , progesterone receptor , HER2 ) LABC ( stage IIB , IIIA , IIB ) low endocrine responsiveness ( define less 50 % tumor cell stain hormone receptor ) , Grade 3 histological grade , 4 node positive , presence extensive peritumoral vascular invasion , OR pathological tumor size great 5 cm LABC ( stage IIB , IIIA , IIB ) ER negative 2 . Evidence preexist peripheral neuropathy determine baseline Michigan neuropathy screen instrument score &gt; 2 . 3 . Previous chemotherapy treatment kind . 4 . AST ALT &gt; 2 time upper limit normal ; Creatinine &gt; 2.0 mg/dL . 5 . Current use medication substance know associated peripheral neuropathy . 6 . Use ALA antioxidant supplement prior three month . 7 . Diabetes mellitus use medication know low blood sugar . 8 . Participation experimental trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>peripheral neuropathy</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>breast cancer</keyword>
</DOC>